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Introduction
Research Design
Conclusions
We hypothesize that myr-PKCβII+ would increase fMLP or PMA -induced PMN SO 
release, whereas, myr-PKCβII- would decrease this response as compared to non-drug 
treated controls.  We further predict that unconjugated, native PKCβII+/- peptide 
sequences would not differ from non-drug treated controls.
1. Myr-PKCβII+ significantly increased PMA-induced PMN SO release (from 180 to 240 
sec.) and myr-PKCβII- significantly decreased both PMA and fMLP-induced PMN SO 
release (~ entire time-course). Native PKCβII+/- did not significantly attenuate PMA or 
fMLP induced PMN SO release as compared to non-drug treated controls. The results 
support our hypothesis except for the effects of PKCβII+ on fMLP-induced SO release.
2. These results  suggest that: (1) Myristic acid conjugation is superior to native peptide 
in delivering the cargo sequence to augment or inhibit PKCβII translocation. (2) PKCβII 
is a principle PKC isoform that regulates PMN NOX-2 activity. (3) Myr-PKCβII+ may 
induce desensitization of the PMN chemotactic receptor in fMLP-induced SO release 
and may be responsible for the blunted SO release with this putative activator of PKCβII 
translocation. (4) The current data support that treatment with myr-PKCβII- would be an 
effective strategy to limit inflammation-induced (i.e. PMNs) tissue damage in heart 
attack patients or organ transplant recipients upon the restoration of blood flow.
3. Future studies: (1a) To test a myr-conjugated scrambled PKC βII+ or βII - to further 
evaluate the proposed mechanism of action (augmentation or inhibition of PKCβII 
translocation) of the cargo sequences (SVEIWD [PKCβII+] or SLNPEWNET [PKCβII-
]). (1b) To conduct western blotting of native/myr-conjugated PKCβII+ or PKCβII- and 
their myr-scrambled peptide counterparts in treated PMN cell lysates. 
Results
Isolation of PMNs. Male Sprague-Dawley rats (350-400g, Charles River, Springfield 
MA) under anesthesia of 2.5% isoflurane were injected intraperitoneally (I.P.) with 16ml 
of 0.5% glycogen dissolved in PBS to cause accumulation of PMNs. After 16–18h, rats 
were re-anesthetized with isoflurane and the PMNs were harvested by peritoneal lavage 
as previously described (5,7).  
Measurement of SO Release From Rat PMNs. The SO release from PMNs was 
measured spectrophotometrically by the reduction of ferricytochrome c and superoxide 
dismutase (SOD) 10µg/ml was used as positive control, as previously described (3,5,7). 
Please refer to schematic diagram below:  
Hypothesis
Activation of protein kinase C beta II (PKCβII) is known to stimulate polymorphonuclear
leukocyte (PMN) NADPH oxidase (NOX-2) to produce superoxide (SO). PKCβII is 
dependent on diacylglycerol (DAG) and calcium for its activation. Activated PKCβII then 
binds to its selective receptor for activated C kinase (RACK) which enhances PKCβII 
translocation to the cell membrane and subsequent phosphorylation of membrane bound 
proteins (1,2).  Of these, PKCβII phosphorylation of NOX-2 generates SO release (Figs. 1 and 
2).  PKCβII can be activated by both phorbol 12-myristate 13-acetate (PMA) and N-formyl-L-
methionyl-L-leucyl-L-phenylalanine (fMLP).  PMA, a lipid soluble broad-spectrum PKC 
agonist, is a DAG mimetic that directly activates PKCβII.  fMLP is a chemotactic receptor 
agonist that directly activates PKCβII via the G-protein signaling cascade (see Fig. 1). 
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Figure 2. Illustration of PKCβII+/-. PKCβII+ and PKCβII- both bind to the Ca2+ binding domain within
the RACK binding site (i.e., C2-4 region;) of PKCβII to regulate its translocation to the cell membrane to
phosphorylate its substrate (top; Adapted from 3). PKCβII+ mechanism of action is to increase PKCβII
translocation via RACK binding to interact with substrates, like NOX-2, while PKCβII- inhibits that
interaction (bottom; Adapted from 2).
Figure 3. PMA (100nM) induced maximal PMN SO release at 330 sec to 0.41±0.04 in non-drug treated 
controls. PMA-induced PMN SO release was significantly increased by myr-PKCβII+ from 180 to 240 sec 
(P<0.05 vs. control ) and generated maximal SO release at 360-390 sec.(0.49±0.05). By contrast, myr-
PKCβII- significantly decreased  SO release to 0.26±0.04) at 360-390sec.  SOD (n=8) reduced SO release 
>90% (not shown). Cell viability was >95% in all groups (not shown).
Figure 4.  fMLP (1μM) induced maximal PMN SO release at 60 sec to 0.18±0.02 in non-drug 
controls and was significantly decreased by myr-PKCβII- (0.08±0.02) at 60 sec. By contrast, 
myr-PKCβII+ increased  to (0.11±0.03) at 30 sec. was not different from non-drug treated 
controls.  Native PKCβ+/- peptides were not different from non-drug controls throughout the time-
course.  SOD (n=8) reduced SO release >90% (not shown).  Cell viability was >95% in all groups 
(not shown).
Inhibition of tissue NOX-2 attenuates the inflammation mediated vascular injury seen in 
various diseases, including diabetes, myocardial infarction and organ transplantation (4). 
Previously, a myristoylated (myr-) selective PKCβII RACK peptide inhibitor (N-myr-
SLNPEWNET; myr-PKCβII-) was found to dose dependently inhibit PMA and fMLP-induced 
PMN SO release and myocardial ischemia/reperfusion (MI/R) injury via the mechanism 
depicted in Figure 2 (3,5,6).  Myristoylation of peptides is known to potentiate their entry into 
the cell via simple diffusion through the cell membrane to affect PKC activity (7).  However, 
the role of myr-PKCβII RACK peptide activator (N-myr-SVEIWD; myr-PKCβII+) on 
regulation of PMN SO release has not been studied (8). The aim of the current study is to 
compare the effects of myr-PKCβII+/- on fMLP or PMA-induced PMN SO release. 
Statistical Analysis
All data in the text and figures are presented as means ± S.E.M. The data were 
analyzed by ANOVA using the Fisher’s PLSD test. Probability values of <0.05 are 
considered to be statistically significant.
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Figure 1. Schematic representation of 
PKCβII role in stimulating SO release in 
PMNs. PMN chemotactic G-protein 
receptors are activated by fMLP. Activated 
receptor stimulates phospholipase C beta 
(PLCβ) to produce second messengers, 
inositol 1,4,5 trisphosphate (Ins(1,4,5)P2) 
and DAG  respectively from phosphatidyl
inositol 4,5 bisphosphate (Ptdlns(4,5)P2). 
Ins(1,4,5)P2 stimulates Ca2+ release from 
the endoplasmic reticulum (ER). Ca2+ and 
DAG directly activate PKCβII.  PMA also 
directly activates PKCβII. Activated 
PKCβII phosphorylates NADPH oxidase, 
which then releases SO (Adapted from 3).
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